The government discharged the CEO of Kimia Farma following the company’s big losses. It was the aftermath of inefficient joint venture manufacturing operation.

The management of Indofarma is designing a plan to rescue the company. Waiting for projects from the government.

The BPK detected Rp371.83 billion worth of fund diversion at Indofarma. Money from a number of subsidiaries was siphoned off through problematic transactions.

Kimia Farma and the holding of state-owned pharmaceutical companies have an excess stock of vaccines that are nearing their expiration date. The state could suffer losses.

The pharmaceutical industry weakened after reaping profits during the Covid-19 pandemic. Private companies are considered more efficient than state-owned enterprises.

The government has yet to set the scheme for paid booster vaccines. The chaos surrounding the Gotong Royong Vaccination program threatens to rear its head again.

The government opens up opportunities for private parties to participate in the market of paid booster vaccinations starting in 2022. It is seen as a violation of the law on pandemics.

Galvanized by alarming spikes in numbers of positive cases and deaths resulting from the Delta variant of Covid-19, Bio Farma is accelerating the production of Covid-19 vaccines. Yet, vaccine stocks remain stagnant with uneven distribution in many regions. With a production capacity of up to 6 million doses per week or 250 million doses a year, Bio Farma’s CEO Honesti Basyir hopes that the company can fulfill the country’s vaccine need.